microRNAs are a family of small non protein-coding RNAs. They are involved in post-transcriptional gene regulation of their target genes. The deregulation of microRNAs has been linked to cancer development and tumor progression. The aim of out study was to look for microRNA-141 as a diagnostic and prognostic biomarker for prostate cancer. The study prospectively recruited 30 patients newly diagnosed with prostate cancer; including 13 and 17 patients without and with metastases, respectively. Another 30 patients without prostate cancer diagnosis were included as a control group. Real-time polymerase chain reaction analysis was done for relative quantification of microRNA-141. The present study showed that microRNA-141 was significantly upregulated in cancerous patients compared to control group. Also it was significantly upregulated in patients with metastatic disease compared to non-metastatic patients. Moreover, it was significantly correlating with serum PSA and Gleason score. Serum microRNA-141 could be a promising diagnostic and prognostic biomarker for prostate cancer and a good indicative of disease aggressiveness.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: